Moleculin Biotech, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Moleculin Biotech, Inc. has filed an Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, primarily to include previously omitted Part III information regarding directors, executive compensation, and corporate governance.
NASDAQ
Moleculin Biotech files an amendment to its 2024 annual report to include certain interactive data file tagging and restate items 10 through 14.
NASDAQ
10-K/A: Moleculin Biotech Files Amendment No. 1 to Form 10-K/A to Include Omitted Part III Information
Moleculin Biotech files an amendment to its annual report to include information about directors, executive officers, corporate governance, executive compensation, security ownership, related party transactions, and principal accountant fees.
NASDAQ
Moleculin Biotech's 10-K filing highlights progress in Annamycin's clinical development, particularly the Phase 3 MIRACLE trial for relapsed/refractory AML, while navigating financial constraints and regulatory landscapes.
NASDAQ
Moleculin Biotech has filed an amendment to its annual report to include information about directors, executive compensation, and corporate governance, which was previously omitted.
NASDAQ
Moleculin Biotech's 10-K filing highlights ongoing clinical trials for Annamycin and other drug candidates, along with financial results for 2023.